Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$386M Sell
1,774,415
-34,292
-2% -$7.61M 0.7% 12
2025
Q4
$413M Buy
1,808,707
+518,767
+40% +$118M 0.7% 14
2025
Q3
$299M Buy
1,289,940
+254,429
+25% +$51.8M 0.52% 24
2025
Q2
$192M Buy
1,035,511
+423,451
+69% +$78.7M 0.37% 46
2025
Q1
$128M Sell
612,060
-161,966
-21% -$31.5M 0.33% 60
2024
Q4
$138M Sell
774,026
-47,301
-6% -$8.7M 0.36% 41
2024
Q3
$162M Sell
821,327
-61,637
-7% -$11.5M 0.42% 33
2024
Q2
$151M Sell
882,964
-367,300
-29% -$60.8M 0.38% 38
2024
Q1
$228M Buy
1,250,264
+10,515
+0.8% +$1.81M 0.57% 20
2023
Q4
$192M Buy
+1,239,749
New +$181M 0.54% 23
2023
Q3
Sell
-872,821
Closed -$128M 18
2023
Q2
$118M Buy
+872,821
New +$128M 0.36% 44
2023
Q1
Sell
-480,672
Closed -$73.5M 87
2022
Q4
$77.7M Buy
480,672
+227,138
+90% +$34.8M 0.28% 72
2022
Q3
$34M Buy
+253,534
New +$36.4M 0.16% 160
2022
Q2
Sell
-389,831
Closed -$59.6M 94
2022
Q1
$63.2M Buy
389,831
+52,279
+15% +$7.59M 0.22% 100
2021
Q4
$45.7M Buy
337,552
+4,080
+1% +$482K 0.15% 152
2021
Q3
$36M Buy
333,472
+29,045
+10% +$3.32M 0.13% 176
2021
Q2
$34.3M Sell
304,427
-117,301
-28% -$13.2M 0.12% 177
2021
Q1
$45.6M Sell
421,728
-287,672
-41% -$30.8M 0.2% 113
2020
Q4
$76M Sell
709,400
-816,393
-54% -$78.5M 0.33% 56
2020
Q3
$134M Sell
1,525,793
-219,350
-13% -$20.7M 0.53% 29
2020
Q2
$171M Sell
1,745,143
-137,133
-7% -$12.1M 0.86% 17
2020
Q1
$143M Sell
1,882,276
-1,137,749
-38% -$96.9M 0.93% 15
2019
Q4
$267M Sell
3,020,025
-19,813
-0.7% -$1.64M 0.88% 9
2019
Q3
$230M Buy
3,039,838
+434,570
+17% +$29.8M 0.86% 9
2019
Q2
$189M Buy
2,605,268
+1,636,248
+169% +$129M 0.68% 14
2019
Q1
$78.1M Buy
969,020
+839,173
+646% +$68.7M 0.3% 59
2018
Q4
$12M Sell
129,847
-25,553
-16% -$2.25M 0.05% 399
2018
Q3
$14.7M Sell
155,400
-16,777
-10% -$1.59M 0.05% 441
2018
Q2
$16M Sell
172,177
-895,883
-84% -$87.5M 0.07% 342
2018
Q1
$101M Buy
+1,068,060
New +$117M 0.46% 35

Other funds holding ABBV

Man Group's ABBV Position: Q1 2026 in Review

Man Group reduced its AbbVie (ABBV) stake by 1.9% in Q1 2026, selling an estimated $7.61M and leaving 1,774,415 shares worth $386M. The position accounts for 0.7% of the portfolio, ranked #12.

Man Group first reported a position in ABBV in Q1 2018 and has held it in 30 quarters since. The position peaked at $413M in Q4 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Man Group held 1,774,415 shares of AbbVie worth $386M as of Q1 2026.
  • Man Group sold 34,292 AbbVie shares in Q1 2026, an estimated $7.61M.
  • AbbVie made up 0.7% of Man Group's portfolio in Q1 2026, its #12 holding.
  • Man Group first reported a position in AbbVie in Q1 2018 and has held it in 30 quarters since.
  • Man Group's AbbVie position peaked at $413M in Q4 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.